Skip to main content

Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.

Publication ,  Journal Article
Taghipour, M; Sheikhbahaei, S; Trahan, TJ; Subramaniam, RM
Published in: Nucl Med Commun
June 2016

OBJECTIVE: To evaluate the accuracy and value of the fourth and subsequent post-therapy follow-up fluorine-18 fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) scans in the clinical assessment of breast cancer patients. MATERIALS AND METHODS: Ninety-two female patients, with a total of 426 fourth and subsequent follow-up PET/CT scans, were retrospectively included. Patients were followed for a median of 23.7 months (range, 0.7-124.4) from the fourth follow-up PET/CT. The diagnostic accuracy of PET/CT, its impact on clinical assessment, patients' management, and survival outcome were established. RESULT: Of the 426 follow-up PET/CT scans, 264 (62%) were interpreted as positive and 162 (38%) were interpreted as negative. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the fourth and subsequent follow-up PET/CT scans were 97.7, 98.1, 98.8, 96.3, and 97.9%, respectively. Fourth and subsequent follow-up PET/CT were useful in excluding a tumor in 13.4% (39/292) of patients with a clinical suspicion of recurrence and identifying suspected recurrence in 10.5% (14/134) of patients without previous clinical suspicion. A change in management was noted in 6.7% (9/134) of scan times when the scans were performed without previous clinical suspicion of recurrence or therapy response and was 27.7% (81/292) when the scans were performed with clinical suspicion. Overall survival differed significantly between patients with all negative follow-up scans (n=23) and those who had at least one positive follow-up scan (n=69) (hazard ratio of 4.65, P<0.001). CONCLUSION: The fourth and subsequent PET/CT scans performed after the completion of primary treatment led to a change in management in 27.7% of patients when the scans were performed with clinical suspicion and only in 6.7% of patients when performed without clinical suspicion or context.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nucl Med Commun

DOI

EISSN

1473-5628

Publication Date

June 2016

Volume

37

Issue

6

Start / End Page

602 / 608

Location

England

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Sensitivity and Specificity
  • Risk Factors
  • Retrospective Studies
  • Reproducibility of Results
  • Radiopharmaceuticals
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Taghipour, M., Sheikhbahaei, S., Trahan, T. J., & Subramaniam, R. M. (2016). Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. Nucl Med Commun, 37(6), 602–608. https://doi.org/10.1097/MNM.0000000000000491
Taghipour, Mehdi, Sara Sheikhbahaei, Tyler J. Trahan, and Rathan M. Subramaniam. “Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.Nucl Med Commun 37, no. 6 (June 2016): 602–8. https://doi.org/10.1097/MNM.0000000000000491.
Taghipour M, Sheikhbahaei S, Trahan TJ, Subramaniam RM. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. Nucl Med Commun. 2016 Jun;37(6):602–8.
Taghipour, Mehdi, et al. “Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.Nucl Med Commun, vol. 37, no. 6, June 2016, pp. 602–08. Pubmed, doi:10.1097/MNM.0000000000000491.
Taghipour M, Sheikhbahaei S, Trahan TJ, Subramaniam RM. Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. Nucl Med Commun. 2016 Jun;37(6):602–608.

Published In

Nucl Med Commun

DOI

EISSN

1473-5628

Publication Date

June 2016

Volume

37

Issue

6

Start / End Page

602 / 608

Location

England

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Sensitivity and Specificity
  • Risk Factors
  • Retrospective Studies
  • Reproducibility of Results
  • Radiopharmaceuticals
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Middle Aged